IP Library Granted Patent US 10,716,810
Granted Patent B2
US 10,716,810 · App. 16/044,347 · Granted Jul 21, 2020

Canine autologous immunotherapy using dendritic cell induced cancer killing immunocytes

Inventors: Thomas Ichim (San Diego, CA); David Koos (La Mesa, CA)
Assignee: Zander Therapeutics, Inc.
A61K35/17A61K39/0011C12N5/0638C12N5/0639A61K2039/5154A61K2039/552C12N2501/22C12N2501/2302C12N2501/2304C12N2501/51C12N2501/515C12N2501/998C12N2502/1114C12N2506/115
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,716,810
App. No.
16/044,347
Granted
Jul 21, 2020
Kind
B2
Abstract

Described are compositions of matter, protocols, and treatment means for induction of immune mediated killing in dogs suffering from cancer. The invention provides means of extracting peripheral blood from a canine patient, expanding immunocytes capable of killing cancer cells in vitro, and re-administering said immunocytes into a patient in need of therapy. In one embodiment, immunocytes expanded are T cells possessing tumor cytotoxic activity induced by stimulation of NKG2D.

Claims (1)

1. A method of treating cancer in dog by generating immunocytes capable of killing cancer cells in a dog, said method comprising the steps of: a) obtaining canine blood; b) culturing peripheral blood mononuclear cells (PBMCs) isolated from said canine blood with a water-soluble acidic peptidoglycan (WSPG) from sprouts of the plant Solanum tuberosum at a concentration and time frame sufficient to induce cytolytic activity against canine tumor cells; and c) expanding said cells in vitro prior to administration in vivo, and d) administering said expanded cells into a dog suffering from cancer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2022
From: ZANDER THERAPEUTICS INC.
To: ZANDER BIOLOGICS INC.
Reel/Frame 059121/0909 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2018
From: KOOS, DAVID; ICHIM, THOMAS
To: ZANDER THERAPEUTICS, INC.
Reel/Frame 047807/0551 →
Continuity (3)
Division 15225484 · Aug 1, 2016
Provisional Application 62199256 · Jul 31, 2015
Related Publication 20190000879A1 · Jan 3, 2019